P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines
- 21 July 2003
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 25 (8) , 654-661
- https://doi.org/10.1002/hed.10274
Abstract
Background. A critical factor for successful organ preservation treatment in head and neck cancer may be selecting tumors that respond to chemotherapy and radiation. Previous results in patients indicated that tumors that overexpressed p53 were more sensitive to chemotherapy than those that did not overexpress p53. Methods. To determine the relationship of p53 mutations to sensitivity to cisplatin in vitro, 23 head and neck squamous cell carcinoma (HNSCC) cell lines were analyzed for cisplatin sensitivity, p53 expression, and p53 mutation status. Results. Mutations of the p53 gene were identified in 13 of 23 of the cell lines tested. Mutation of the p53 gene was significantly associated with high levels of expression of the p53 protein. The average ID50 (drug dose required to inhibit 50% of cell growth) for cell lines with mutant p53 was 6.8 μM, whereas the average ID50 for cell lines with wild-type p53 was 13.7 μM. Conclusions. These in vitro data support a role for mutation of the p53 tumor suppressor gene as a marker for response to cisplatin in HNSCC. © 2003 Wiley Periodicals, Inc. Head Neck 25: 654–661, 2003Keywords
This publication has 25 references indexed in Scilit:
- Expression of Bcl‐2 Family Proteins in Advanced Laryngeal Squamous Cell Carcinoma: Correlation With Response to Chemotherapy and Organ PreservationThe Laryngoscope, 2002
- VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLSJournal of Urology, 2001
- A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradationOncogene, 2001
- Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomasInternational Journal of Cancer, 2001
- The role of the E6-p53 interaction in the molecular pathogenesis of HPVOncogene, 1999
- The interaction between p53 and papillomavirusesSeminars in Cancer Biology, 1999
- Accumulation of Mutant p53V143A Modulates the Growth, Clonogenicity, and Radiochemosensitivity of Malignant Glioma Cells Independent of Endogenous p53 StatusExperimental Cell Research, 1999
- p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell CarcinomaJNCI Journal of the National Cancer Institute, 1996
- Flexibility: the key to p53 function?Trends in Biochemical Sciences, 1995
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991